Literature DB >> 22212011

Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.

M Rashid1, M Karimi.   

Abstract

AIM/
OBJECTIVE: Iran is located on the Mediterranean belt and has high prevalence of thalassaemia. Deferoxamine therapy requires burdensome hours of daily infusion several times a week.
METHODS: We studied 510 thalassaemia major patients referring to thalassaemia tertiary care centre for compliance of deferoxamine and also assessed various reasons for non-compliance. A questionnaire was developed.
RESULTS: Our study showed that 418 (82%) subjects were adherent to deferoxamine therapy. Females were more adherent to the chelation therapy. Among patients whose age was ≤ 12 years, 90.4% showed drug compliance compared with 80.3% in patients aged >12 years (P = 0.03). The most frequently reported reason for poor compliance was pain (38%).
CONCLUSION: High percentage of patients had adherence to iron chelation, which is in contrast to previous studies. This may be attributed to the vigorous efforts of governmental and non-governmental organisations in educating patients and provision of free drug and equipment in the past few years. The results were satisfying but still more is to be done to increase drug adherence and to minimise reasons causing poor compliance.
© 2011 The Authors. Transfusion Medicine © 2011 British Blood Transfusion Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212011     DOI: 10.1111/j.1365-3148.2011.01130.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  2 in total

Review 1.  Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients.

Authors:  Chinea Eziefula; Farrukh T Shah; Kofi A Anie
Journal:  Patient Prefer Adherence       Date:  2022-06-07       Impact factor: 2.314

2.  A pilot study on sperm DNA damage in β-thalassemia major: is there a role for antioxidants?

Authors:  Heba Elsedfy; Vincenzo De Sanctis; Alaa Youssef Ahmed; Noha Refaat Mohamed; Mohamed Arafa; Mohsen Saleh Elalfy
Journal:  Acta Biomed       Date:  2018-03-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.